Resident Esophageal Microbiota Dysbiosis Correlates with Cancer Risk in Barrett's Esophagus Patients and Is Linked to Low Adherence to WCRF/AICR Lifestyle Recommendations.
diet
esophageal adenocarcinoma
microbiota
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
26 Jun 2023
26 Jun 2023
Historique:
received:
30
05
2023
revised:
19
06
2023
accepted:
20
06
2023
medline:
17
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
Esophageal adenocarcinoma (EAC) is the consequence of longstanding gastroesophageal reflux, which leads to inflammation and could cause Barrett's esophagus (BE), the main risk factor for EAC development. The 5 year survival rate of EAC is poor since the diagnosis occurs at the late stage of the disease. To improve patient management, a better comprehension of the mechanism undergoing the evolution through to adenocarcinoma is needed. Within this scenario, the resident microbiome investigation was studied. This study aimed to explore the esophageal microbial profile in patients affected by non-dysplastic BE, low- and high-grade dysplastic BE, and EAC to identify parameters characterizing cancer progression and to develop a score suitable for clinical practice to stratify cancer risk. The microbiota was investigated through the 16S rRNA gene sequencing of esophageal biopsies. The microbial composition was evaluated at each different taxonomic level along the disease progression. To further investigate bacteria potentially associated with cancer development, non-dysplastic and dysplastic/cancer patients were compared. The presence of the six significant microbial features with multivariate analysis was used to develop a multiparametric score (Resident Esophageal Microbial Dysbiosis Test) to predict the risk of progression toward EAC. Finally, the diagnostic ability of the test and its discrimination threshold for its ability to identify dysplastic/cancer patients were demonstrated. Since EAC has been related to obesity, the relationship between these microbial parameters and patients' diet/lifestyle habits was also investigated. Developing microbiome-based risk prediction models for esophageal adenocarcinoma onset could open new research avenues, demonstrating that the resident microbiome may be a valid cancer risk biomarker.
Identifiants
pubmed: 37447211
pii: nu15132885
doi: 10.3390/nu15132885
pmc: PMC10343580
pii:
doi:
Substances chimiques
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Istituto Oncologico Veneto
ID : Ricerca Corrente IOV-IRCCS 2016-2019
Organisme : Italian Ministry of Health
ID : Ricerca Finalizzata Grant RF-2016-02363566
Organisme : Centro di Riferimento Oncologico di Aviano
ID : Ricerca Corrente CRO-IRCCS 2022.
Références
Cancer Epidemiol Biomarkers Prev. 2019 Oct;28(10):1687-1693
pubmed: 31466948
Gut. 2017 Aug;66(8):1441-1448
pubmed: 27797940
Front Cell Infect Microbiol. 2023 May 19;13:1145791
pubmed: 37274313
Int J Cancer. 2019 May 1;144(9):2099-2108
pubmed: 30374967
Clin Transl Gastroenterol. 2018 Oct 25;9(10):199
pubmed: 30356041
Lancet Gastroenterol Hepatol. 2017 Jan;2(1):32-42
pubmed: 28404012
Appl Environ Microbiol. 2014 Feb;80(3):1142-9
pubmed: 24296500
Microorganisms. 2021 Nov 22;9(11):
pubmed: 34835527
PLoS One. 2020 May 5;15(5):e0231789
pubmed: 32369505
Gastroenterology. 2009 Aug;137(2):588-97
pubmed: 19394334
Nat Rev Cancer. 2020 Feb;20(2):125-138
pubmed: 31848467
Medicine (Baltimore). 2021 Mar 19;100(11):e25138
pubmed: 33725995
Prog Mol Biol Transl Sci. 2020;176:1-42
pubmed: 33814111
JAMA. 2013 Aug 14;310(6):627-36
pubmed: 23942681
Br J Cancer. 2016 Feb 2;114(3):237-42
pubmed: 26730578
Environ Microbiol. 2014 Sep;16(9):2905-14
pubmed: 24112768
World J Gastroenterol. 2015 May 7;21(17):5210-9
pubmed: 25954094
Front Oncol. 2020 Sep 10;10:1727
pubmed: 33014854
Am J Clin Nutr. 2013 May;97(5):1107-20
pubmed: 23553166
Front Oncol. 2021 Oct 18;11:717242
pubmed: 34733778
J Med Microbiol. 2018 Aug;67(8):1058-1068
pubmed: 29923815
Clin Infect Dis. 2007 Jul 1;45(1):29-38
pubmed: 17554697
BMC Microbiol. 2009 Jun 09;9:123
pubmed: 19508720
Cancers (Basel). 2023 Apr 30;15(9):
pubmed: 37174041
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
BMJ. 2014 Jun 10;348:g3437
pubmed: 24916719
Front Oncol. 2021 Mar 12;11:627270
pubmed: 33777773
Nutrients. 2020 Jan 02;12(1):
pubmed: 31906573
Cancer Metastasis Rev. 2022 Jun;41(2):281-299
pubmed: 35511379
Eur J Clin Invest. 2011 Apr;41(4):417-22
pubmed: 21114493
Cell Mol Gastroenterol Hepatol. 2022;13(3):857-874
pubmed: 34506954
Gastroenterology. 2019 Aug;157(2):492-506.e2
pubmed: 30998992
Lancet Oncol. 2017 Aug;18(8):e457-e471
pubmed: 28759385
Nutrients. 2021 Oct 17;13(10):
pubmed: 34684639
Microbiome. 2018 Dec 17;6(1):227
pubmed: 30558669
Eur J Nutr. 2016 Jun;55(4):1563-71
pubmed: 26155779
Nutrients. 2019 Oct 02;11(10):
pubmed: 31581675
PLoS One. 2012;7(9):e42938
pubmed: 22957025
Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4250-5
pubmed: 15016918
Cancer Causes Control. 2015 Feb;26(2):277-286
pubmed: 25559553